COL4A5内含子第3至5位变异导致Alport综合征
本研究在Alport综合征队列中鉴定出11个COL4A5内含子第3至5位变异,通过微小基因体外剪接实验证实所有变异均导致异常剪接,其中6例患者样本体内分析验证了该结果,商业剪接预测软件准确预测了10个变异的剪接改变。
要点
- COL4A5内含子第3至5位变异可导致异常剪接,应纳入XLAS诊断评估。
- 微小基因剪接实验是验证此类变异致病性的有效方法。
- 商业剪接预测软件对10/11个变异预测准确。
核心结论
- COL4A5内含子第3至5位变异可导致异常剪接,对XLAS诊断和预后评估具有重要意义。
研究设计与样本
- 从2006年1月至2022年7月的Alport综合征队列中鉴定11个COL4A5内含子第3至5位变异,采用微小基因体外剪接实验、商业软件剪接预测及患者样本mRNA分析。
主要发现
- 所有11个变异在微小基因剪接实验中均显示异常剪接模式。
- 6例患者样本体内分析证实了异常剪接。
- 商业剪接预测软件准确预测了10个变异的剪接改变。
临床怎么用
- 对COL4A5内含子第3至5位变异应进行剪接评估以辅助XLAS诊断和预后判断。
局限性
- 需进一步研究确认这些变异的致病性及其对XLAS肾脏预后的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Alport syndrome (AS) is an inherited kidney disease caused by variants in the COL4A3, COL4A4, or COL4A5 genes, resulting in type IV collagen abnormalities. Although autosomal dominant variants in COL4A3 and COL4A4 are increasingly being diagnosed, X-linked AS (XLAS) caused by COL4A5 variants predominates. Single nucleotide substitutions in introns positioned at first and second from the last nucleotide (called a consensus sequence) of exons always cause aberrant splicing. However, whether intronic variants at the third to fifth positions from the last nucleotide of exons can cause aberrant splicing is unclear. METHODS: We identified 11 intronic variants positioned at the third, fourth, and fifth nucleotides from the exon 3' end in COL4A5 from our AS cohort (January 2006-July 2022). We conducted in vitro splicing assays using minigenes and in silico splicing analysis using commercial splicing prediction software and evaluated mRNA sequences obtained from patients' samples when available. RESULTS: All 11 patients showed aberrant splicing patterns in the minigene splicing assays. In vivo analysis of 6 patients corroborated these findings. The commercial splicing prediction software accurately predicted splicing changes in 10 variants. CONCLUSIONS: This study shows that 11 intronic variants at the third to fifth positions in COL4A5 introns cause aberrant splicing. This finding highlights the importance of evaluating such variants for the diagnosis and prognosis of XLAS. Further investigation is warranted to confirm the pathogenicity of these variants and their effect on the prognosis of the kidney in XLAS.
引用
- Kitakado H, Horinouchi T, Aoyama S, et al. COL4A5 Intronic Variants at Third to Fifth Nucleotides Cause Alport Syndrome. Kidney Int Rep. 2024. PMID: 39990911. doi:10.1016/j.ekir.2024.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。